Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4463151
Max Phase: Preclinical
Molecular Formula: C38H47FN4O9
Molecular Weight: 722.81
Molecule Type: Unknown
Associated Items:
ID: ALA4463151
Max Phase: Preclinical
Molecular Formula: C38H47FN4O9
Molecular Weight: 722.81
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C=C1C(=O)O[C@H]2[C@H]1CC/C(COC(=O)CCC(=O)NCCCCCCNC(=O)Cn1cc(F)c(=O)n(Cc3ccccc3)c1=O)=C\CC[C@@]1(C)O[C@@H]21
Standard InChI: InChI=1S/C38H47FN4O9/c1-25-28-15-14-27(13-10-18-38(2)34(52-38)33(28)51-36(25)48)24-50-32(46)17-16-30(44)40-19-8-3-4-9-20-41-31(45)23-42-22-29(39)35(47)43(37(42)49)21-26-11-6-5-7-12-26/h5-7,11-13,22,28,33-34H,1,3-4,8-10,14-21,23-24H2,2H3,(H,40,44)(H,41,45)/b27-13+/t28-,33-,34-,38+/m0/s1
Standard InChI Key: VYMJSWWASZASIK-SFECBYKGSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 722.81 | Molecular Weight (Monoisotopic): 722.3327 | AlogP: 3.07 | #Rotatable Bonds: 16 |
Polar Surface Area: 167.33 | Molecular Species: NEUTRAL | HBA: 11 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 13 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 3.18 | CX LogD: 3.18 |
Aromatic Rings: 2 | Heavy Atoms: 52 | QED Weighted: 0.09 | Np Likeness Score: 0.59 |
1. Ding Y, Li S, Ge W, Liu Z, Zhang X, Wang M, Chen T, Chen Y, Zhang Q.. (2019) Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma., 183 [PMID:31553932] [10.1016/j.ejmech.2019.111706] |
Source(1):